Gabelli & Co. Initiates Coverage on CPEX Pharmaceuticals (CPEX) with a Buy
More News related to CPEX
- Arcadia Capital Advisors Managing Director Richard S. Rofe Comments on CPEX Pharmaceuticals' Failed Nasulin Phase 2a Trial
- CPEX Pharmaceuticals Files Preliminary Proxy Materials and Nominates Highly Qualified Independent Board Candidate for Election at 2010 Annual Meeting
- CPEX Pharma (CPEX) Updates on Nasulin Phase 2a
- CPEX Pharmaceuticals Announces Preliminary Results from its Phase 2a Clinical Trial of Nasulin(TM)
- CPEX Pharmaceuticals, Inc. (CPEX) Swings to Q4 Loss of $0.20
Gabelli & Co. initiates coverage on CPEX Pharmaceuticals, Inc (Nasdaq: CPEX) with a Buy. Price target $17.
Gabelli analyst says, "The market appears to be valuing CPEX Pharmaceuticals based on the company's nasal insulin product, Nasulin; we feel that this does not adequately reflect the value of the company's Testim royalty stream - we expect that the Paragraph IV generic drug filing against Testim and the increased R&D expenses to support Nasulin will continue to be a drag on the stock, however several catalysts could emerge over the next 12-18 months: settlement with Upsher-Smith, early termination/partnering of Nauslin, success of MannKind's Technosphere Insulin, new partnership opportunities, and the possibility of acquisition."
CPEX Pharmaceuticals, Inc. is a specialty pharmaceutical company.
Related Categories
New CoverageStocks Mentioned
-0.51Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
